Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Lenalidomide plus low-dose dexamethasone for relapsed or refractory B-cell acute lymphoblastic leukemia
2009-009372-13Phase 2Active
- Sponsor
- Institut de Cancérologie Lucien Neuwirth
- Start
- Sep 2009
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of lenalidomide and dexamethasone in B cell acute lymphoblastic leukemia (B-ALL), sponsored by Institut de Cancérologie Lucien Neuwirth. Primary endpoints: Complete response rate, Complete response without platelet reconstitution rate and 2 more. Started Sep 2009; status: active.
02
Drugs
lenalidomidedexamethasone
03
Conditions
B cell acute lymphoblastic leukemia (B-ALL)
Beyond the preview
Go deeper on 2009-009372-13.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2009-009372-13.